New paradigms for Hsp90 inhibition
New paradigms for Hsp90 inhibition
批准号:
9762054
负责人:
Brian S J Blagg
金额:
$34.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2021-08-31
关键词:
Amino AcidsAntineoplastic AgentsBindingBinding SitesCardiotoxicityCell ProliferationClientClinical TrialsComplexCrystallizationDataDevelopmentDiseaseDoseDrug DesignEvaluationExhibitsFrequenciesGenerationsHSP 90 inhibitionHeat shock proteinsHeat-Shock ResponseHepatotoxicityIn VitroIndividualLeadMAPK7 geneMalignant NeoplasmsMaximum Tolerated DoseMethodsMolecular ChaperonesMolecular ConformationN-terminalPatientsPeripheral Nervous System DiseasesPharmaceutical ChemistryPharmaceutical PreparationsProcessPropertyProtein IsoformsProteinsReportingScheduleSideSignal TransductionStructureToxic effectValidationantitumor agentbasecancer therapycell growthclinical candidatecomputer studiesdrug developmentin vivoinhibitor/antagonistmyelinationneuropeptide Ynovel strategiesprotein degradationprotein foldingresearch clinical testingside effectsmall molecule inhibitor
中文摘要
90 kDa热休克蛋白(Hsp90)负责大约200种客户蛋白的成熟
底物,其中大多数与调节细胞生长的信号级联相关,
增殖因此,Hsp90抑制提供了一种治疗癌症的新方法,
通过抑制Hsp90依赖性蛋白质折叠,
过程在本申请中,我们提出开发Hsp90亚型,Grp94,Hsp90α,
和Hsp90β,使用结构引导的方法。此外,我们还将对这些产品进行并排评估,
化合物对泛抑制剂在体外和体内,以验证我们的方法。总之,这些方法
将为选择性抑制Hsp90提供新的途径,并将为抗癌提供新的范例
药物开发
英文摘要
The 90 kDa heat shock proteins (Hsp90) are responsible for the maturation of approximately 200 client protein
substrates, most of which are associated with signaling cascades that regulate cellular growth and
proliferation. Therefore, Hsp90 inhibition provides a novel approach toward the treatment of cancer as
numerous signaling cascades can be derailed through inhibition of the Hsp90-dependent protein folding
process. In this application, we propose to develop selective inhibitors of the Hsp90 Isoforms, Grp94, Hsp90α,
and Hsp90β, using a structure-guided approach. In addition, we will perform side by side evaluation of these
compounds against pan-inhibitors both in vitro and in vivo to validate our approach. Together, these methods
will provide a new approach for selective inhibition of Hsp90 and will provide a new paradigm for anti-cancer
drug development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering the Next Generation of Safer Hsp90 Inhibitors
-
批准号:10587304
-
项目类别:
-
资助金额:$46.33万
-
财政年份:2023
-
负责人:Brian S J Blagg
-
依托单位:
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors
-
批准号:9514012
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Hsp90B in Bladder Cancer
-
批准号:9922232
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Optimization and Investigation of Cruentaren A analogs
-
批准号:9454428
-
项目类别:
-
资助金额:$34.25万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Optimization and Investigation of Cruentaren A analogs
-
批准号:9902368
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors
-
批准号:9600723
-
项目类别:
-
资助金额:$44.39万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
Optimization and Investigation of Cruentaren A analogs
-
批准号:10078544
-
项目类别:
-
资助金额:$35.3万
-
财政年份:2018
-
负责人:Brian S J Blagg
-
依托单位:
New paradigms for Hsp90 inhibition
-
批准号:10000886
-
项目类别:
-
资助金额:$35.41万
-
财政年份:2017
-
负责人:Brian S J Blagg
-
依托单位:
New paradigms for Hsp90 inhibition
-
批准号:9379940
-
项目类别:
-
资助金额:$36.66万
-
财政年份:2017
-
负责人:Brian S J Blagg
-
依托单位:
Grp94-selective inhibitors to treat heredity glaucoma
-
批准号:8928624
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2014
-
负责人:Brian S J Blagg
-
依托单位:
Grp94-selective inhibitors to treat heredity glaucoma
-
批准号:8785724
-
项目类别:
-
资助金额:$43.54万
-
财政年份:2014
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8636503
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8297562
-
项目类别:
-
资助金额:$31.82万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8413041
-
项目类别:
-
资助金额:$30.68万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Development of Hsp90 inhibitors for the treatment of cancer
-
批准号:8456077
-
项目类别:
-
资助金额:$29.3万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Development of Hsp90 inhibitors for the treatment of cancer
-
批准号:8627592
-
项目类别:
-
资助金额:$30.29万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
Chaperone therapeutics for the treatment of DPN
-
批准号:8824587
-
项目类别:
-
资助金额:$31.73万
-
财政年份:2012
-
负责人:Brian S J Blagg
-
依托单位:
COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS & PROTEINS
-
批准号:7720669
-
项目类别:
-
资助金额:$2.61万
-
财政年份:2008
-
负责人:Brian S J Blagg
-
依托单位:
HSP90 Inhibitors
-
批准号:8184864
-
项目类别:
-
资助金额:$24.43万
-
财政年份:2006
-
负责人:Brian S J Blagg
-
依托单位:
Hsp90 Inhibitors
-
批准号:7038182
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2006
-
负责人:Brian S J Blagg
-
依托单位:
海外基金